menu
    • menu

    Company profile for Curia

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners turn their ideas into real-world impact. We partner closely with pharmaceutical and biotechnology companies to boost business performance and improve patients’ lives. From early discovery and development through manufacturing and commercialization, ou...
    Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners turn their ideas into real-world impact. We partner closely with pharmaceutical and biotechnology companies to boost business performance and improve patients’ lives. From early discovery and development through manufacturing and commercialization, our suite of custom solutions allows us to tailor every engagement to your precise needs, whether that’s an independent project or an opportunity that cuts across the drug continuum.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CuriaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    26 Corporate Circle, Albany, New York 12203
    Telephone
    Telephone
    +1 518.512.2000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://curiaglobal.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/curia-cdmo
    youtube
    YouTube
    Twitter
    Twitter
    https://twitter.com/CuriaCDMO

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI India 2024

    CPhI India 2024

    Not Confirmed

    envelop Contact Supplier

    CPhI India 2024

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Due to its 20-year mastery in micronization, Inke has emerged a cornerstone in treating global respiratory diseases”

    “Due to its 20-year mastery in micronization, Inke has emerged a cornerstone in treating global respiratory diseases”

    This week, SpeakPharma interviews Miquel Bachs, CEO of Inke, a company with over two decades of expertise in micronization and particle engineering, and a leader in providing high-quality, effective solutions in the global fight against chronic respiratory diseases such as COPD and asthma. In this insightful conversation, Bachs shares Inke’s strategic vision, technological innovations, and commitment to sustainability, offering a comprehensive look at how the company is shaping the future of respiratory health. HIGHLIGHTS// Inke’s strategic vision/ technological innovations/ commitment to sustainability Studies suggest that 13 percent of people over 40 years of age, the world over, have chronic obstructive pulmonary disease (COPD). Given the increasing prevalence of respiratory diseases, how does Inke position itself as a leader in the development and manufacturing of respiratory APIs? Inke has established itself as a global leader in generic respiratory API development through our unique blend  of technological innovation, expertise in micronization, and a comprehensive portfolio of inhalation therapies. With over 20 years of experience in micronization and particle engineering, our ability to customize APIs to meet specific client requirements has resulted in highly effective, high-quality products tailored for respiratory therapies. The increasing prevalence of chronic respiratory diseases, such as COPD and asthma, has only underscored Inke’s pivotal role in supporting the pharmaceutical industry’s need for advanced treatments. We specialize in bronchodilators and other critical respiratory APIs that improve patient outcomes and meet the stringent regulatory requirements of global health authorities. Our end-to-end approach, from early-stage API development to commercial-scale production, ensures that we maintain the highest standards of quality, safety, and efficacy. As the market for respiratory APIs continues to evolve, Inke remains committed to expanding its portfolio to address unmet therapeutic needs. Beyond respiratory APIs, we are also prioritizing growth in CNS treatments and building on our expertise in complex molecule synthesis. This strategic focus allows us to provide an integrated solution that not only meets current market demands but also anticipates future pharmaceutical trends. HIGHLIGHTS// comprehensive portfolio of inhalation therapies/ over 20 years of experience in micronization and particle engineering/ specialize in bronchodilators and other critical respiratory APIs/ prioritizing growth in CNS treatments In the field of micronization, what differentiates Inke’s approach from that of other manufacturers of respiratory APIs? What sets Inke apart in micronization is our advanced particle size reduction technology and our dedication to precision. Our facility is equipped with various milling techniques such as Cone, Jet, and Pin mills, allowing us to reduce particle size while stabilizing the amorphous content to ensure consistent quality. Our in-depth understanding of respiratory APIs, combined with our ability to tailor solutions for each customer, results in APIs with improved solubility, stability, and bioavailability, which are critical for the efficacy of inhalation products. This, along with our exceptional quality standards and a flawless audit track record, has positioned us as a key partner for major players in the inhalation market. HIGHLIGHTS// advanced particle size reduction technology/ technological innovations/ tailor solutions/ improved solubility, stability, and bioavailability Developing complex APIs can be challenging. How does Inke ensure a smooth and successful partnership throughout the development and manufacturing process, including customization, ensuring regulatory compliance and timely delivery? At Inke, we are dedicated to fostering strong partnerships with our clients through a collaborative approach that prioritizes open communication and mutual understanding. Our commitment to quality and personalized service sets us apart in the pharmaceutical landscape. Our team takes the time to engage in comprehensive discussions to customize our solutions, ensuring alignment with client specifications across all batches and grades. This commitment to flexibility allows us to respond effectively to evolving requirements, solidifying Inke’s reputation as a reliable partner. We understand that navigating regulatory landscapes can be challenging. That's why our team is equipped to manage all aspects of the regulatory process with meticulous attention to detail. From the submission of Drug Master Files (DMFs) and Certificates of Suitability to crafting precise responses to potential Deficiency Letters, we ensure compliance at every step. Moreover, we offer extensive support in patent and intellectual property matters, providing technical assistance and guidance tailored to the specific requirements of each region. Our unwavering dedication to quality, coupled with our agile response capabilities, enables us to deliver exceptional results while maintaining transparency and trust. At Inke, we are committed to building lasting relationships that drive success for both our clients and our organization. HIGHLIGHTS// ensuring alignment with client specifications/ manage all aspects of the regulatory process/ support in patent and intellectual property matters Given Inke’s global presence, what are the key markets for growth and how does Inke plan to expand its market reach and strengthen its position in these regions? Inke is strategically focused on expanding its footprint in the European and US markets, where we continue to prioritize our efforts. The US market remains pivotal for us, especially considering our successful FDA inspections and ongoing regulatory compliance efforts that solidify our reputation. Japan is another significant market where we have established a robust presence, reflecting our commitment to high-quality manufacturing and innovation. Looking ahead, China represents a key growth opportunity for Inke. With 12 active DMFs registered, we are well-positioned to tap into this burgeoning market. Our strategy involves leveraging our existing capabilities to navigate regulatory landscapes and fostering strong partnerships within the region, thereby enhancing our market reach and influence in the pharmaceutical sector. HIGHLIGHTS// expanding footprint in the European and US markets/ China represents a key growth opportunity for Inke With Inke expanding into contract manufacturing organization (CMO) services, how does this new offering align with Inke’s broader strategic goals, and what advantages does it provide to pharmaceutical partners? At Inke, the introduction of CMO services is a natural extension of our core expertise in the development and manufacturing of high-quality generic APIs. Our expansion into CMO is part of a strategic move to diversify our service portfolio, allowing us to offer end-to-end solutions for our clients. The CMO service integrates seamlessly with our expertise in API manufacturing, particularly in micronization, which has been a key differentiator for Inke for over two decades. With our advanced particle engineering capabilities, we can offer tailored solutions that meet specific technical and regulatory requirements. Whether it is small-batch production or scaling up to commercial quantities, we offer the flexibility to accommodate a wide range of customer needs. This adaptability, paired with our deep expertise in micronization, allows us to support evolving project needs, maintaining the highest standards of consistency, quality, and performance that define Inke’s footprint. HIGHLIGHTS// CMO is part of a strategic move to diversify our service portfolio/ deep expertise in micronization What is Inke’s commitment to sustainability and corporate social responsibility and how is it integrating sustainable practices into its operations and product development? At Inke, we recognize that integrating environmental, social, and governance (ESG) principles into our operations is not just a responsibility but a pathway to long-term success. Our ESG vision is centered around aligning business growth with sustainable practices that positively impact our communities and the environment. We are dedicated to environmental responsibility, actively implementing initiatives such as efficient wastewater treatment and water reuse systems to minimize our ecological footprint. Our recent investments in energy efficiency include the installation of a 135 kWp solar panel system, which underscores our commitment to reducing emissions and resource consumption across our manufacturing and research facilities. Inke is also committed to fostering a diverse and inclusive workforce. With a notable increase in our team members, particularly in operations and quality assurance, we prioritize career development and the well-being of our employees. By adhering to high regulatory standards, we ensure our products meet stringent global requirements, enhancing our transparency and compliance. Through these initiatives, Inke aims to cultivate sustainable practices that not only support our business objectives but also contribute positively to the pharmaceutical industry and society at large. HIGHLIGHTS// integrating ESG principles/ efficient wastewater treatment and water reuse systems/ installation of a 135 kWp solar panel system/ diverse and inclusive workforce

    Impressions: 441

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases

    #SpeakPharma With Inke
    28 Oct 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2508

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Curia Commits to SBTi Net-Zero Standard
    Curia Commits to SBTi Net-Zero Standard

    08 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/10/08/2959748/0/en/Curia-Commits-to-SBTi-Net-Zero-Standard.html

    GLOBENEWSWIRE
    08 Oct 2024
    Share Share
    Curia Commits to Greenhouse Gas Emission Reductions
    Curia Commits to Greenhouse Gas Emission Reductions

    08 Oct 2024

    // CONTRACTPHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-10-08/curia-commits-to-greenhouse-gas-emission-reductions/?widget=listSection

    CONTRACTPHARMA
    08 Oct 2024
    Share Share
    Bio X Cell Appoints Christopher Conway CEO
    Bio X Cell Appoints Christopher Conway CEO

    12 Aug 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-08-12/bio-x-cell-appoints-christopher-conway-ceo/72644

    CONTRACT PHARMA
    12 Aug 2024
    Share Share
    Siegfried expands US reach with deal for Wisconsin facility
    Siegfried expands US reach with deal for Wisconsin facility

    13 Jun 2024

    // Joseph Keenan FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/cdmo-siegfried-expands-us-footprint-acquisition-wisconsin-facility

    Joseph Keenan FIERCE PHARMA
    13 Jun 2024
    Share Share
    Curia And Carterra Partner On Biologics Symposium
    Curia And Carterra Partner On Biologics Symposium

    09 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/09/2878810/0/en/Curia-and-Carterra-Partner-on-Biologics-Symposium-to-Further-Biotechnology-Research-in-the-Pacific-Northwest.html

    GLOBENEWSWIRE
    09 May 2024
    Share Share
    Curia And Carterra Host Biologics Symposium For Pacific Northwest Biotech
    Curia And Carterra Host Biologics Symposium For Pacific Northwest Biotech

    09 May 2024

    // PRESS RELEASE

    https://curiaglobal.com/news/curia-and-carterra-partner-on-biologics-symposium-to-further-biotechnology-research-in-the-pacific-northwest/

    PRESS RELEASE
    09 May 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Betamethasone Dipropionate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Betamethasone Dipropionate

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-10-05

    Pay. Date : 2015-09-24

    DMF Number : 17046

    Submission : 2003-12-23

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2002-031 - Rev 03

    Issue Date : 2021-08-24

    Type : Chemical

    Substance Number : 809

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10367

    Registrant's Address : Parque Tecnologico-Parcela 105 Boecillo (Valladolid) Spain

    Initial Date of Registration : 2007-12-13

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65089-0009

    Start Marketing Date : 1984-10-10

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Betamethasone Sodium Phosphate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Betamethasone Sodium Phosphate

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2023-12-07

    Pay. Date : 2023-09-27

    DMF Number : 38831

    Submission : 2023-09-20

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2023-167 - Rev 00

    Issue Date : 2023-08-23

    Type : Chemical and TSE

    Substance Number : 810

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10235

    Registrant's Address : Parque Tecnologico-Parcela 105 Boecillo (Valladolid) Spain

    Initial Date of Registration : 2007-07-06

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65089-0004

    Start Marketing Date : 1965-03-03

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Clobetasol Propionate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Clobetasol Propionate

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 26191

    Submission : 2012-06-29

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2011-095 - Rev 01

    Issue Date : 2021-08-25

    Type : Chemical

    Substance Number : 2127

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 222MF10016

    Registrant's Address : Parque Tecnologico-Parcela 105 Boecillo (Valladolid) Spain

    Initial Date of Registration : 2010-01-07

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65089-0003

    Start Marketing Date : 1994-02-16

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF arrow-down
    ✖

    Registrant Name : JDW Pharmaceutical Co., Ltd.

    Registration Date : 2011-08-12

    Registration Number : 20080530-93-E-56-03(5)

    Manufacturer Name : Crystal Pharma, SA,

    Manufacturer Address : Parque Tecnologico de Boecillo, Parcela 105, 47151-Boecillo (Valladolid), Spain

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Cyclosporine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Cyclosporine

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-01-16

    Pay. Date : 2013-12-02

    DMF Number : 12949

    Submission : 1998-04-13

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 1999-034 - Rev 06

    Issue Date : 2021-08-30

    Type : Chemical

    Substance Number : 994

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 218MF10617

    Registrant's Address : Via del Vecchio Politecnico n. 9, 20121 Milano (MI) - Italy

    Initial Date of Registration : 2006-07-03

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 55486-1567

    Start Marketing Date : 2012-06-03

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : AbbVie Korea Inc.

    Registration Date : 2015-06-18

    Registration Number : 20150618-18-C-338-07

    Manufacturer Name : Curia Italy Srl

    Manufacturer Address : Via Volturno, 41/43 - 20089 ROZZANO (MI), Italy

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Dorzolamide Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Dorzolamide Hydrochloride

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-09-21

    Pay. Date : 2013-09-11

    DMF Number : 18385

    Submission : 2005-05-31

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2010-115 - Rev 03

    Issue Date : 2021-11-15

    Type : Chemical

    Substance Number : 2359

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 227MF10011

    Registrant's Address : Parque Tecnologico-Parcela 105 Boecillo (Valladolid) Spain

    Initial Date of Registration : 2015-01-05

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65089-0039

    Start Marketing Date : 1994-12-09

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Samil Pharmaceutical Co., Ltd.

    Registration Date : 2023-01-06

    Registration Number : 20211115-209-J-1151(B)

    Manufacturer Name : CURIA SPAIN SAU

    Manufacturer Address : Parque Tecnológico de Boecillo, Parcela 105. 47151 Boecillo, Valladolid, Spain

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Hydrocortisone

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Hydrocortisone

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-01-07

    Pay. Date : 2018-09-18

    DMF Number : 33002

    Submission : 2018-07-31

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2018-045 - Rev 02

    Issue Date : 2024-10-21

    Type : Chemical

    Substance Number : 335

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 217MF10680

    Registrant's Address : Parque Tecnologico-Parcela 105 Boecillo (Valladolid) Spain

    Initial Date of Registration : 2005-10-07

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65089-0056

    Start Marketing Date : 1982-01-01

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Minocycline Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Minocycline Hydrochloride

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-01-30

    Pay. Date : 2013-01-16

    DMF Number : 14802

    Submission : 2000-03-22

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2000-107 - Rev 10

    Issue Date : 2024-02-27

    Type : Chemical

    Substance Number : 1030

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 217MF10699

    Registrant's Address : Via del Vecchio Politecnico n. 9, 20121 Milano (MI) - Italy

    Initial Date of Registration : 2005-10-07

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 44657-0051

    Start Marketing Date : 2010-07-01

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (30kg/30kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Propofol

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Propofol

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-07-21

    Pay. Date : 2014-07-11

    DMF Number : 10868

    Submission : 1994-04-20

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2001-267 - Rev 04

    Issue Date : 2021-08-11

    Type : Chemical

    Substance Number : 1558

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 218MF10529

    Registrant's Address : Via del Vecchio Politecnico n. 9, 20121 Milano (MI) - Italy

    Initial Date of Registration : 2006-05-18

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 44657-0044

    Start Marketing Date : 2010-10-20

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (5kg/5kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF arrow-down
    ✖

    VMF Number : 5894

    Submission : 2007-06-01

    Status : Active

    Type : II

     Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Flutamide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Flutamide

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 12807

    Submission : 1997-12-17

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2000-049 - Rev 07

    Issue Date : 2024-09-10

    Type : Chemical

    Substance Number : 1423

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 44657-0048

    Start Marketing Date : 2012-03-28

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (25kg/25kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Ribavirin

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    SupplySide West 2024
    Not Confirmed
    arrow

    Ribavirin

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-01-17

    Pay. Date : 2014-01-14

    DMF Number : 15700

    Submission : 2001-10-30

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2007-182 - Rev 03

    Issue Date : 2021-08-11

    Type : Chemical

    Substance Number : 2109

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 44657-0076

    Start Marketing Date : 2012-03-15

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (25kg/25kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    1-lzd

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    02

    31/ac Hcl

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    03

    5-thiazole Wing

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    04

    A-84538.0 (ritonavir)

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    05

    Alcaftadine

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    Alcaftadine

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Curia

    GDUFA

    DMF Review : Complete

    Rev. Date : 2014-04-11

    Pay. Date : 2014-02-24

    DMF Number : 27982

    Submission : 2014-02-18

    Status : Active

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Alclometasone Dipropionate

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    07

    Altrenogest

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    08

    Amphetamine Aspartate

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    09

    Amphetamine Aspartate, Monohydrate D...

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow

    10

    Amphetamine Sulfate Usp

    U.S.A
    SupplySide West 2024
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    VMF

    read-more
    read-more

    01

    PODD Partnership
    Not Confirmed
    arrow

    02

    PODD Partnership
    Not Confirmed
    arrow

    03

    PODD Partnership
    Not Confirmed
    arrow

    04

    PODD Partnership
    Not Confirmed
    arrow

    05

    PODD Partnership
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Curia Supports Replicate Bioscience's Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

    Details:

    RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.


    Lead Product(s): RBI-4000

    Therapeutic Area: Infections and Infectious Diseases Brand Name: RBI-4000

    Study Phase: Phase IProduct Type: Vaccine

    Recipient: Replicate Bioscience

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 13, 2023

    blank

    01

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RBI-4000

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Recipient : Replicate Bioscience

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Curia Supports Replicate Bioscience's Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

    Details : RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

    Brand Name : RBI-4000

    Molecule Type : Vaccine

    Upfront Cash : Not Applicable

    September 13, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Gl...

    Details:

    Murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and to generate high affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.


    Lead Product(s): Murine Monoclonal Antibody

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Large molecule

    Sponsor: Tonix Pharmaceuticals Holding Corp

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 12, 2022

    blank

    02

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Murine Monoclonal Antibody

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Tonix Pharmaceuticals Holding Corp

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humaniz...

    Details : Murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and to generate high affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    December 12, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

    Details:

    IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.


    Lead Product(s): Cannabidiol,Isoflurane

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: IHL-216A

    Study Phase: PreclinicalProduct Type: Small molecule

    Recipient: Incannex Healthcare

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement August 02, 2022

    blank

    03

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cannabidiol,Isoflurane

    Therapeutic Area : Trauma (Emergency, Injury, Surgery)

    Highest Development Status : Preclinical

    Recipient : Incannex Healthcare

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

    Details : IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.

    Brand Name : IHL-216A

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    August 02, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    First Patient Dosed in the ENLIGHTEN Biomarker-Guided Global Clinical Trial of DB104 (Liafensine) for Treatment-Resistant Depression

    Details:

    Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.


    Lead Product(s): Liafensine

    Therapeutic Area: Psychiatry/Psychology Brand Name: DB104

    Study Phase: Phase IIProduct Type: Small molecule

    Recipient: Denovo Biopharma

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 28, 2022

    blank

    04

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Liafensine

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Recipient : Denovo Biopharma

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    First Patient Dosed in the ENLIGHTEN Biomarker-Guided Global Clinical Trial of DB104 (Liafensine) ...

    Details : Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.

    Brand Name : DB104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 28, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

    Details:

    As part of the collaboration, Curia’s experienced process development team will support the GMP production of Replicate Bioscience’s srRNA vectors up to eight-liter scale (8L), which can be used in Phase 1 through pivotal clinical trials.


    Lead Product(s): srRNA Therapeutic

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Large molecule

    Sponsor: Replicate Bioscience

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration June 09, 2022

    blank

    05

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : srRNA Therapeutic

    Therapeutic Area : Immunology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Replicate Bioscience

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development ...

    Details : As part of the collaboration, Curia’s experienced process development team will support the GMP production of Replicate Bioscience’s srRNA vectors up to eight-liter scale (8L), which can be used in Phase 1 through pivotal clinical trials.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    June 09, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Curia Named Exclusive API Supplier for Recently Approved Acne Treatment

    Details:

    Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.


    Lead Product(s): Clascoterone

    Therapeutic Area: Dermatology Brand Name: Winlevi

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Cassiopea

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement October 30, 2020

    blank

    06

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clascoterone

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Cassiopea

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Curia Named Exclusive API Supplier for Recently Approved Acne Treatment

    Details : Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.

    Brand Name : Winlevi

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 30, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1

    Details:

    Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.


    Lead Product(s): Bryostatin-1

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Small molecule

    Recipient: BryoLogyx Inc

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 13, 2020

    blank

    07

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bryostatin-1

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Recipient : BryoLogyx Inc

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1

    Details : Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.

    Brand Name : Undisclosed

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 13, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Curia Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine

    Details:

    Curia has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at Curia’s drug product manufacturing facility in Albuquerque, New Mexico.


    Lead Product(s): ChAdOx1 nCoV-19

    Therapeutic Area: Infections and Infectious Diseases Brand Name: AZD1222

    Study Phase: Phase IIIProduct Type: Vaccine

    Sponsor: AstraZeneca

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement September 03, 2020

    blank

    08

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ChAdOx1 nCoV-19

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Curia Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine

    Details : Curia has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at Curia’s drug product manufacturing facility in Albuquerque, New Mexico.

    Brand Name : AZD1222

    Molecule Type : Vaccine

    Upfront Cash : Undisclosed

    September 03, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tryp Therapeutics Partners with Curia to Manufacture a Proprietary Psilocybin-based Drug

    Details:

    Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.


    Lead Product(s): Psilocybine

    Therapeutic Area: Psychiatry/Psychology Brand Name: TRP-8802

    Study Phase: UndisclosedProduct Type: Small molecule

    Sponsor: Tryp Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership August 13, 2020

    blank

    09

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Psilocybine

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Tryp Therapeutics

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Tryp Therapeutics Partners with Curia to Manufacture a Proprietary Psilocybin-based Drug

    Details : Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.

    Brand Name : TRP-8802

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    August 13, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ViralClear, Curia Enter COVID-19 Partnership

    Details:

    The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.


    Lead Product(s): Merimepodib,Remdesivir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: VX-497

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: BioSig Technologies

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership July 08, 2020

    blank

    10

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Curia

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Merimepodib,Remdesivir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : BioSig Technologies

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    ViralClear, Curia Enter COVID-19 Partnership

    Details : The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.

    Brand Name : VX-497

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    July 08, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Upload your portfolio for free, ask us

    Analytical

    Click here to discover the service providers for Analytical

    API Manufacturing

    Click here to discover the service providers for API Manufacturing

    Drug Product Manufacturing

    Click here to discover the service providers for Drug Product Manufacturing

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Excipients by Ingredients

    Upload your portfolio for free, ask us

    Excipients By applications

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    Others

    read-more
    read-more

    ABOUT THIS PAGE

    Contact Curia and get a quotation

    Curia is a supplier offers 168 products (APIs, Excipients or Intermediates).

    Find a price of Betamethasone Dipropionate bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Betamethasone Sodium Phosphate bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Clobetasol Propionate bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Cyclosporine bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Dorzolamide Hydrochloride bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Hydrocortisone bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Minocycline Hydrochloride bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Propofol bulk with DMF, CEP, JDMF offered by Curia

    Find a price of Alclometasone Dipropionate bulk with DMF, JDMF offered by Curia

    Find a price of Betamethasone Valerate bulk with CEP, JDMF offered by Curia

    Find a price of Brimonidine Tartrate bulk with DMF, CEP offered by Curia

    Find a price of Bromocriptine Mesylate bulk with DMF, CEP offered by Curia

    Find a price of Budesonide bulk with DMF, CEP offered by Curia

    Find a price of Chlorthalidone bulk with DMF, CEP offered by Curia

    Find a price of Desogestrel bulk with DMF, CEP offered by Curia

    Find a price of Dexamethasone bulk with CEP, JDMF offered by Curia

    Find a price of Dexamethasone Sodium Phosphate bulk with DMF, CEP offered by Curia

    Find a price of Dihydroergotamine Mesylate bulk with DMF, CEP offered by Curia

    Find a price of Ergotamine Tartrate bulk with DMF, CEP offered by Curia

    Find a price of Exemestane bulk with DMF, CEP offered by Curia

    Find a price of Fentanyl bulk with DMF, CEP offered by Curia

    Find a price of Fentanyl Citrate bulk with DMF, CEP offered by Curia

    Find a price of Flutamide bulk with DMF, CEP offered by Curia

    Find a price of Fluticasone Propionate bulk with DMF, CEP offered by Curia

    Find a price of Furosemide bulk with DMF, CEP offered by Curia

    Find a price of Hydrocortisone Butyrate bulk with DMF, JDMF offered by Curia

    Find a price of Mifepristone bulk with DMF, JDMF offered by Curia

    Find a price of Mometasone Furoate bulk with DMF, CEP offered by Curia

    Find a price of Olopatadine Hydrochloride bulk with DMF, JDMF offered by Curia

    Find a price of Pancuronium Bromide bulk with DMF, CEP offered by Curia

    Find a price of Pramipexole Dihydrochloride bulk with DMF, CEP offered by Curia

    Find a price of Prednisolone Sodium Phosphate bulk with DMF, JDMF offered by Curia

    Find a price of Ribavirin bulk with DMF, CEP offered by Curia

    Find a price of Rocuronium Bromide bulk with DMF, CEP offered by Curia

    Find a price of Testosterone bulk with DMF, CEP offered by Curia

    Find a price of Triamcinolone Acetonide bulk with DMF, JDMF offered by Curia

    Find a price of Ulipristal Acetate bulk with DMF, JDMF offered by Curia

    Find a price of Vecuronium Bromide bulk with DMF, JDMF offered by Curia

    Find a price of Alcaftadine bulk with DMF offered by Curia

    Find a price of Altrenogest bulk with DMF offered by Curia

    Find a price of Amphetamine bulk with DMF offered by Curia

    Find a price of Amphetamine Aspartate bulk with DMF offered by Curia

    Find a price of Argatroban bulk with DMF offered by Curia

    Find a price of Atropine Sulfate bulk with DMF offered by Curia

    Find a price of Azelastine Hydrochloride bulk with DMF offered by Curia

    Find a price of Aztreonam bulk with DMF offered by Curia

    Find a price of Beclomethasone Dipropionate bulk with CEP offered by Curia

    Find a price of Benztropine bulk with DMF offered by Curia

    Find a price of Betamethasone Butyrate Propionate bulk with JDMF offered by Curia

    Find a price of Betamethasone Sodium Phosphate bulk with CEP offered by Curia

    Find a price of Brexanolone bulk with DMF offered by Curia

    Find a price of Butabarbital bulk with DMF offered by Curia

    Find a price of Butorphanol Tartrate bulk with DMF offered by Curia

    Find a price of Cannabidiol bulk with DMF offered by Curia

    Find a price of Carbimazole bulk with CEP offered by Curia

    Find a price of CAS 71-58-9 bulk with CEP offered by Curia

    Find a price of Choline Fenofibrate bulk with DMF offered by Curia

    Find a price of Cifenline bulk with JDMF offered by Curia

    Find a price of Clascoterone bulk with DMF offered by Curia

    Find a price of Cyclofenil bulk with JDMF offered by Curia

    Find a price of Cyclosporine bulk with DMF offered by Curia

    Find a price of Cyproterone Acetate bulk with CEP offered by Curia

    Find a price of Deoxycholic Acid bulk with DMF offered by Curia

    Find a price of Dexamethasone bulk with JDMF offered by Curia

    Find a price of Dexmethylphenidate bulk with DMF offered by Curia

    Find a price of Dextroamphetamine Saccharate bulk with DMF offered by Curia

    Find a price of Diatrizoate Meglumine bulk with DMF offered by Curia

    Find a price of Diatrizoate Sodium bulk with DMF offered by Curia

    Find a price of Dihydroergocristine bulk with CEP offered by Curia

    Find a price of Dihydroergotoxine Mesylate bulk with DMF offered by Curia

    Find a price of Dihydrolysergic Acid Amide bulk with DMF offered by Curia

    Find a price of Drospirenone bulk with CEP offered by Curia

    Find a price of Echothiophate Iodide bulk with DMF offered by Curia

    Find a price of Epinephrine bulk with DMF offered by Curia

    Find a price of Ethanolamine Oleate bulk with DMF offered by Curia

    Find a price of Etonogestrel bulk with DMF offered by Curia

    Find a price of Finasteride bulk with CEP offered by Curia

    Find a price of Fludrocortisone Acetate bulk with DMF offered by Curia

    Find a price of Fluorometholone bulk with DMF offered by Curia

    Find a price of Fluoxymesterone bulk with DMF offered by Curia

    Find a price of Hexetidine bulk with CEP offered by Curia

    Find a price of Homoharringtonine bulk with DMF offered by Curia

    Find a price of Hydrochloric Acid bulk with DMF offered by Curia

    Find a price of Hydrocortisone bulk with DMF offered by Curia

    Find a price of Hydrocortisone Acetate bulk with CEP offered by Curia

    Find a price of Hydrocortisone Sodium Succinate bulk with CEP offered by Curia

    Find a price of Hydroxychloroquine Sulphate bulk with DMF offered by Curia

    Find a price of Isosorbide Mononitrate bulk with CEP offered by Curia

    Find a price of L-Tartaric Acid bulk with DMF offered by Curia

    Find a price of Lacosamide bulk with DMF offered by Curia

    Find a price of Levocabastine bulk with CEP offered by Curia

    Find a price of Loteprednol Etabonate bulk with DMF offered by Curia

    Find a price of Mac321 bulk with DMF offered by Curia

    Find a price of Mafenide bulk with DMF offered by Curia

    Find a price of Mecamylamine bulk with DMF offered by Curia

    Find a price of Mecamylamine Hydrochloride bulk with DMF offered by Curia

    Find a price of Medroxyprogesterone Acetate bulk with DMF offered by Curia

    Find a price of Methylphenidate Hydrochloride bulk with DMF offered by Curia

    Find a price of Methylprednisolone Acetate bulk with DMF offered by Curia

    Find a price of Metolazone bulk with DMF offered by Curia

    Find a price of Milrinone bulk with JDMF offered by Curia

    Find a price of Minocycline Hydrochloride bulk with DMF offered by Curia

    Find a price of Monomethyl Fumarate bulk with DMF offered by Curia

    Find a price of Mycophenolate Sodium bulk with DMF offered by Curia

    Find a price of Naltrexone Methobromide bulk with DMF offered by Curia

    Find a price of Nepafenac bulk with DMF offered by Curia

    Find a price of Niflumic Acid bulk with CEP offered by Curia

    Find a price of Norepinephrine Bitartrate bulk with DMF offered by Curia

    Find a price of Olopatadine Hydrochloride bulk with DMF offered by Curia

    Find a price of Oxandrolone bulk with DMF offered by Curia

    Find a price of Pentetic Acid bulk with DMF offered by Curia

    Find a price of Pentobarbital Sodium bulk with DMF offered by Curia

    Find a price of Pethidine Hydrochloride bulk with DMF offered by Curia

    Find a price of Pimecrolimus bulk with DMF offered by Curia

    Find a price of Pralidoxime Chloride bulk with DMF offered by Curia

    Find a price of Prednisone bulk with DMF offered by Curia

    Find a price of Pyrazole Diamide, 29 bulk with DMF offered by Curia

    Find a price of Regadenoson Monohydrate bulk with DMF offered by Curia

    Find a price of Riboflavin 5 Phosphate Sodium bulk with DMF offered by Curia

    Find a price of Ritalinic Acid bulk with DMF offered by Curia

    Find a price of Ritonavir bulk with DMF offered by Curia

    Find a price of Segesterone Acetate bulk with DMF offered by Curia

    Find a price of Sirolimus bulk with DMF offered by Curia

    Find a price of Sodium Oxybate bulk with DMF offered by Curia

    Find a price of Succinate bulk with DMF offered by Curia

    Find a price of Tapentadol bulk with DMF offered by Curia

    Find a price of Testosterone Cypionate bulk with DMF offered by Curia

    Find a price of Tetrahydrocannabinol bulk with DMF offered by Curia

    Find a price of Thiazole bulk with DMF offered by Curia

    Find a price of Ticlopidine bulk with DMF offered by Curia

    Find a price of Travoprost bulk with DMF offered by Curia

    Find a price of Triamcinolone Acetonide bulk with JDMF offered by Curia

    Find a price of Trientine Hydrochloride bulk with DMF offered by Curia

    Find a price of Upadacitinib bulk with DMF offered by Curia

    Find a price of Viloxazine Hydrochloride bulk with DMF offered by Curia

    Find a price of Vorinostat bulk with DMF offered by Curia

    Find a price of Voxelotor bulk with DMF offered by Curia

    Find a price of KETOENAMINE bulk with DMF offered by Curia

    Find a price of EBAB bulk with DMF offered by Curia

    Find a price of INTERMEDIATE PERG/9 D-6-N-(PROPIONYL)-8BETA-METHYLTHIOMETHYLERGOLINE bulk with DMF offered by Curia

    Find a price of bulk with JDMF offered by Curia

    Find a price of Aripiprazole bulk offered by Curia

    Find a price of Bamifylline bulk offered by Curia

    Find a price of Betamethasone bulk offered by Curia

    Find a price of Betamethasone Acetate bulk offered by Curia

    Find a price of Betamethasone Benzoate bulk offered by Curia

    Find a price of Deflazacort bulk offered by Curia

    Find a price of Deucravacitinib bulk offered by Curia

    Find a price of Diethylamine Salicylate bulk offered by Curia

    Find a price of Dihydroergocryptine bulk offered by Curia

    Find a price of Etrasimod bulk offered by Curia

    Find a price of Flurogestone Acetate bulk offered by Curia

    Find a price of Ganaxolone bulk offered by Curia

    Find a price of Hydroxyethyl Salicylate bulk offered by Curia

    Find a price of Medrogestone bulk offered by Curia

    Find a price of Melengestrol Acetate bulk offered by Curia

    Find a price of Methylprednisolone Aceponate bulk offered by Curia

    Find a price of Methylprednisolone Hemisuccinate bulk offered by Curia

    Find a price of Methylprednisolone Sodium Succinate bulk offered by Curia

    Find a price of Morniflumate bulk offered by Curia

    Find a price of Nifuratel bulk offered by Curia

    Find a price of Paliperidone Palmitate bulk offered by Curia

    Find a price of Prednicarbate bulk offered by Curia

    Find a price of Propacetamol HCl bulk offered by Curia

    Find a price of Samidorphan L-Malate bulk offered by Curia

    Find a price of Tamsulosin bulk offered by Curia

    Find a price of Testosterone Propionate bulk offered by Curia

    Find a price of Zuranolone bulk offered by Curia

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search